Company News: King Pharmaceuticals

Share this article:
King Pharmaceuticals reported full-year revenue up 14% to $1.78 billion. Highlights of the year included the company's acquisition of Alpharma and winning US marketing approval for pain drug Embeda.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions